Showing 1-10 of 11 results for "".
- Matthew J. Zirwas, MDhttps://practicaldermatology.com/profiles/matthew-j-zirwas-md/OKnqNa/
Low-Nickel Diets Show Promise for Contact Dermatitis
https://practicaldermatology.com/conferences/maui-derm-2024/low-nickel-diets-show-promise-for-contact-dermatitis/20256/Matthew Zirwas, MD, discusses his experience with the “low-nickel diet” for patients who have systemic reactions to dietary nickel.- Allergies to Pre-Moistened Wipes on the Risehttps://practicaldermatology.com/news/20140303-allergies_to_pre-moistened_wipes_on_the_rise/2459326/A preservative in pre-moistened hand wipes may be linked to a rise of allergic reactions, according to dermatologist Matthew Zirwas, MD at the Ohio State University Wexner Center. He says manufacturers are increasing use of the preservative as they reduce their dependence on formaldehyde and parago…
Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pContact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.Updates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at The Ohio State University. Specializing in allergic reactions a…
- CSF Kicks Off in Nashvillehttps://practicaldermatology.com/news/csf-kicks-off-in-nashville/2460229/Cosmetic Surgery Forum (CSF), now in its 11th year, has kicked off in Nashville. It’s the meeting’s first time in the Music City, which allows for live injection sessions—a popular meeting highlight. The program covers everything from cannabidiol (CBD) in skincare and platelet-rich plasma (PRP) for…
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3% administered once daily for eight weeks demonstrated statistically sig…
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. is now doing the same for topical roflumilast foam (ARQ-154) for seborrheic dermatitis following an End-of-Pha…
- Prev
- Next